Amarin's Vascepa Momentum Builds Ahead Of Next Week's FDA AdComm

Sales of the triglyceride-lowering medicine soared to $112.4m in the third quarter even before a label expansion that depends on the outcome of a vital US FDA advisory committee meeting on 14 November.

Sales going up — Vascepa sales were fueled by prescription growth

Amarin Corp. PLC's Vascepa (icosapent ethyl) sales grew 103% in the third quarter to $112.4m, reflecting strong prescription expansion even as the company awaits approval from the US Food and Drug Administration for an expanded indication. Revenues for Vascepa for the first nine months of 2019 were $285.3m, an 89% increase over the first nine months of 2018.

A pivotal FDA advisory committee meeting for Vascepa is scheduled for 14 November to discuss a supplemental new drug application...